CRISPR Therapeutics (CRSP) Competitors

Neurocrine Biosciences (NASDAQ:NBIX) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership, analyst recommendations and community ranking.

Do analysts prefer NBIX or CRSP?

Neurocrine Biosciences presently has a consensus price target of $162.00, suggesting a potential upside of 34.18%. CRISPR Therapeutics has a consensus price target of $71.75, suggesting a potential upside of 86.01%. Given CRISPR Therapeutics' higher probable upside, analysts plainly believe CRISPR Therapeutics is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.86
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the media prefer NBIX or CRSP?

In the previous week, Neurocrine Biosciences had 7 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 25 mentions for Neurocrine Biosciences and 18 mentions for CRISPR Therapeutics. Neurocrine Biosciences' average media sentiment score of 1.39 beat CRISPR Therapeutics' score of 0.72 indicating that Neurocrine Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	19 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has better valuation & earnings, NBIX or CRSP?

Neurocrine Biosciences has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.41B	4.95	$341.30M	$2.95	40.93
CRISPR Therapeutics	$35M	95.18	-$366.25M	-$4.52	-8.53

Is NBIX or CRSP more profitable?

Neurocrine Biosciences has a net margin of 14.49% compared to CRISPR Therapeutics' net margin of -981.54%. Neurocrine Biosciences' return on equity of 13.38% beat CRISPR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	14.49%	13.38%	9.73%
CRISPR Therapeutics	-981.54%	-18.46%	-15.79%

Do institutionals & insiders hold more shares of NBIX or CRSP?

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Which has more risk & volatility, NBIX or CRSP?

Neurocrine Biosciences has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500.

Does the MarketBeat Community favor NBIX or CRSP?

Neurocrine Biosciences received 558 more outperform votes than CRISPR Therapeutics when rated by MarketBeat users. Likewise, 77.68% of users gave Neurocrine Biosciences an outperform vote while only 64.46% of users gave CRISPR Therapeutics an outperform vote.

Company	Underperform	Outperform
Neurocrine Biosciences	Outperform Votes 1044 77.68%	Underperform Votes 300 22.32%
CRISPR Therapeutics	Outperform Votes 486 64.46%	Underperform Votes 268 35.54%

Summary

Neurocrine Biosciences beats CRISPR Therapeutics on 14 of the 17 factors compared between the two stocks.